Published in Neuro Oncol on July 01, 2004
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas (SA02) | NCT00881595
PI3Kinase signaling in glioblastoma. J Neurooncol (2010) 1.01
Temozolomide in malignant glioma. Onco Targets Ther (2010) 0.89
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther (2010) 0.85
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 5.21
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 3.69
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res (2000) 3.05
Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 2.95
Angiogenesis and apoptosis. Semin Cancer Biol (2003) 2.86
Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol (2002) 2.40
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol (1998) 2.39
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol (2001) 2.15
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res (1996) 1.68
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol (1998) 1.61
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (1994) 1.37
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2000) 1.19
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol (2001) 1.13
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol (2002) 1.12
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res (2000) 1.09
Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer (1996) 1.08
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro Oncol (2000) 0.99
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol (1993) 0.84
O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res (1991) 0.83
O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells. Exp Hematol (2001) 0.83
A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology (2002) 0.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 2.41
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging (2010) 2.18
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer (2004) 1.81
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol (2006) 1.74
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Intracranial dural metastases. Cancer (2009) 1.59
Advancing the treatment of malignant glioma: act local, think global. Cancer Invest (2004) 1.59
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery (2002) 1.50
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma (2011) 1.45
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol (2005) 1.44
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology (2007) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Maintenance therapy for central nervous system lymphoma with rituximab. Leuk Lymphoma (2009) 1.39
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol (2003) 1.39
Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol (2007) 1.37
Therapeutic challenges in primary CNS lymphoma. Lancet Neurol (2009) 1.36
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol (2008) 1.36
Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer (2009) 1.35
Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol (2005) 1.35
Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol (2010) 1.31
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol (2008) 1.31
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol (2011) 1.25
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol (2002) 1.20
Primary dural lymphomas: a review. Neurosurg Focus (2006) 1.19
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep (2013) 1.16
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer (2005) 1.15
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology (2004) 1.15
Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology (2006) 1.14
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer (2010) 1.11
Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol (2006) 1.11
Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med (2010) 1.09
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2010) 1.08
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer (2012) 1.08
Primary central nervous system lymphoma. Neurol Clin (2007) 1.07
The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol (2008) 1.07
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs (2006) 1.05
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist (2010) 1.05
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res (2011) 1.04
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg (2002) 1.03
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program (2002) 1.02
Current management of metastatic brain disease. Neurotherapeutics (2009) 1.01
Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol (2009) 1.01
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer (2008) 0.99
Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro Oncol (2013) 0.98
Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol (2007) 0.97
Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol (2006) 0.96
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol (2002) 0.96
Salvage temozolomide for prior temozolomide responders. Cancer (2005) 0.95
Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep (2007) 0.95
Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol (2007) 0.95
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol (2009) 0.94
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol (2011) 0.94
Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol (2012) 0.92
Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol (2011) 0.92
Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol (2007) 0.92
Neurological outcome of long-term glioblastoma survivors. J Neurooncol (2009) 0.92
Imaging of lymphoma of the central nervous system, spine, and orbit. Radiol Clin North Am (2008) 0.89
CNS Hodgkin lymphoma. Blood (2008) 0.89
Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys (2012) 0.89
Prognosis and patterns of care in elderly patients with glioma. Cancer (2009) 0.89
Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer (2007) 0.89
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol (2008) 0.88
Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus (2006) 0.88
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma (2012) 0.87
Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol (2005) 0.87
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res (2005) 0.87
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer (2008) 0.87
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer (2007) 0.86
Bevacizumab in recurrent malignant glioma. Curr Neurol Neurosci Rep (2008) 0.85
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol (2011) 0.85
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol (2007) 0.85
Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas. Target Oncol (2010) 0.84
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol (2008) 0.84
Diagnosis and treatment of primary central nervous system lymphoma. Curr Oncol Rep (2005) 0.83
A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Gastrointest Cancer Res (2012) 0.82
Primary central nervous system lymphoma. Curr Oncol Rep (2004) 0.81
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology (2005) 0.81